Google DeepMind co founder Demis Hassabis just raised $2.1 billion for Isomorphic Labs, his AI drug discovery company built to speed up how new medicines are designed.
The company grew out of DeepMind’s AlphaFold breakthroughs and is now building its own AI drug design engine, with active partnerships across major pharma including Novartis, Eli Lilly, and Johnson & Johnson.
The fresh funding round was led by Thrive Capital, with backing from Alphabet, GV, MGX, Temasek, CapitalG, and the UK Sovereign AI Fund, making it one of the biggest AI healthcare bets so far.
The bigger goal is simple but massive: use AI to cut years from traditional drug discovery, lower development costs, and potentially bring treatments to patients much faster.
Follow us (👉
@artificialintelligenceee ) for everything latest from the AI world.
Source: demishassabis/X